13F Holdings
中文EN

CV CapsoVision, Inc

Electromedical & Electrotherapeutic Apparatus · Nasdaq · SEC CIK 1378325 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY6.4%
TTM net income YoY-29.6%
TTM EPS YoY87.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin49.7%
Operating margin-212.1%
Net margin-210.1%
FCF margin-210.3%
EBITDA margin-210.4%

Returns

ROE-125.0%
ROA-100.1%
ROIC (approx.)-99.6%
Asset turnover0.48x

Leverage & solvency

Liabilities / assets19.5%
Debt / equity0.00x
Current ratio5.07x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.00x
Accruals ratio-0.2%
Payout ratio—
Capex / revenue0.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$13.55M$11.76M
Cost of revenue$6.38M$5.38M
Gross profit$7.17M$6.38M
R&D expense$18.31M$15.12M
SG&A expense$6.85M$4.21M
Operating income-$25.52M-$19.92M
Pretax income-$25.29M-$19.89M
Income tax$24,000$11,000
Net income-$25.32M-$19.90M
EBITDA-$25.30M-$19.71M
EPS (basic)-1.03-9.85
EPS (diluted)-1.03-9.85
Weighted avg. shares (diluted)24.56M2.02M
Balance sheet
Receivables$2.50M$2.00M
Inventory$2.99M$2.63M
Current assets$16.67M$14.85M
PP&E, net$611,000$720,000
Total assets$18.16M$16.80M
Current liabilities$4.43M$1.80M
Total liabilities$4.90M$2.69M
Shareholders' equity$13.26M-$129.51M
Shares outstanding46.87M2.09M
Cash flow statement
Operating cash flow-$22.86M-$20.09M
Capital expenditure$90,000$153,000
Free cash flow-$22.95M-$20.24M
Investing cash flow-$90,000-$153,000
Financing cash flow$23.60M$15.07M
Depreciation & amortization$216,000$206,000
Stock-based compensation$826,000$156,000

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.